As Part Of Wave Life Sciences' Ongoing Collaboration With GSK, GSK Has Selected Its First Two Oligonucleotide Programs, GSK Will Provide An Initiation Payment Of $12M
Portfolio Pulse from Benzinga Newsdesk
GSK has initiated the first two oligonucleotide programs with Wave Life Sciences, providing a $12M initiation payment. This marks a significant advancement in their collaboration, focusing on Wave's next-generation GalNAc-siRNA format aimed at achieving best-in-class potency and durability. The collaboration encompasses various modalities, including RNA editing across multiple therapy areas. Additionally, Wave plans to start a clinical trial for its INHBE program targeting obesity by 1Q 2025, utilizing its siRNA technology.
April 23, 2024 | 2:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wave Life Sciences receives a $12M initiation payment from GSK for the first two oligonucleotide programs, highlighting the progress and potential of their collaboration.
The initiation payment from GSK to Wave Life Sciences signifies a strong vote of confidence in Wave's technology and its potential for future revenue growth. This financial boost and the advancement of their collaboration could positively influence investor sentiment and stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90